Perceive Pharma is advancing small-molecule neuroprotective therapeutics with lead pipeline programs in glaucoma and other ophthalmic diseases. The company’s lead candidate is PBI-671, and its Series A proceeds are intended to push the lead glaucoma program to clinical readiness. Perceive was spun out from Perceive Biotherapeutics and leverages genomic screening and retina-cell screening to identify neuroprotective pathways and drug candidates. The company is backed by a syndicate of life-science investors and is a resident of JLABS @ San Diego. Perceive emphasizes first-in-class approaches to prevent vision loss in patients who continue to progress despite current intraocular-pressure–lowering treatments. The team recently added industry veteran Dr. Carol Gallagher to its board to support development and corporate strategy. Perceive Biotherapeutics is developing a deep and diversified pipeline of ophthalmology therapeutics and technologies. Its lead programs target geographic atrophy/age-related macular degeneration (AMD) and glaucoma, with additional undisclosed disease areas in development. The company is a resident of JLABS @ San Diego, part of Johnson & Johnson Innovation’s incubator network, which provides access to lab space, equipment, and entrepreneurial resources. Led by CEO K. Angela Macfarlane and President Anne Rubin, Perceive plans to use new funding to accelerate its lead AMD program into the clinic and continue progress across its ophthalmology pipeline. The company closed a $78M Series B to support these development activities.

Total raised

$93M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2025